Once-Weekly Basal Insulin Fc Demonstrated Similar Glycemic Control to Once-Daily Insulin Degludec in Insulin-Naive Patients With Type 2 Diabetes: A Phase 2 Randomized Control Trial

OBJECTIVE: Basal insulin Fc (BIF) (insulin efsitora alfa; LY3209590), a fusion protein combining a novel single-chain insulin variant with a human IgG Fc domain, is designed for once-weekly basal insulin administration. This phase 2 study assessed the safety and efficacy of BIF versus degludec in in...

Descripción completa

Detalles Bibliográficos
Autores principales: Bue-Valleskey, Juliana M., Kazda, Christof M., Ma, Chenchen, Chien, Jenny, Zhang, Qianyi, Chigutsa, Emmanuel, Landschulz, William, Haupt, Axel, Frias, Juan P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10154646/
https://www.ncbi.nlm.nih.gov/pubmed/36944059
http://dx.doi.org/10.2337/dc22-2396

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10154646/
https://www.ncbi.nlm.nih.gov/pubmed/36944059
http://dx.doi.org/10.2337/dc22-2396

Ejemplares similares